Rahul Banerjee

Rahul Banerjee, MD, FACP is an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine and an Assistant Professor in the Clinical Research Division at Fred Hutch Cancer Center. He is a board-certified hematologist-oncologist specializing in blood cancers, particularly multiple myeloma, AL amyloidosis, and advanced cellular immunotherapies including CAR-T therapy.

Dr. Banerjee completed his medical education at Brown University's Alpert Medical School, followed by residency in Internal Medicine at the Hospital of the University of Pennsylvania where he served as Chief Resident at the Philadelphia VA Medical Center. He completed fellowships in Hematology/Oncology and an advanced fellowship in Bone Marrow Transplantation and Cellular Therapy at the University of California San Francisco. He is board certified in Internal Medicine, Hematology, and Medical Oncology by the American Board of Internal Medicine and is a Fellow of the American College of Physicians.

His clinical interests focus on multiple myeloma, amyloidosis, and lymphoplasmacytic lymphoma, with particular expertise in CAR-T therapy. His research interests center on toxicity management, digital health, and improving the patient experience during cancer treatment. He emphasizes 'precision health care delivery' that considers side effects, quality of life, financial and logistical considerations, and other factors that impact patients' lives beyond just the cancer itself. Because myeloma is an incurable cancer that patients may live with for years, Dr. Banerjee is passionate about minimizing the burden myeloma places on patients' lives.

His extensive publication record includes over 100 peer-reviewed articles focusing on multiple myeloma, cellular immunotherapies, and patient-centered care. His recent research has explored digital health interventions during stem cell transplantation, financial toxicity in hematologic malignancies, and innovations in CAR-T therapy management. Analysis of his most recent publications reveals a strong focus on improving treatment outcomes while reducing patient burden, with particular attention to digital health solutions and precision delivery of care.

• Fellow, American College of Physicians
• Member, International Myeloma Working Group
• Member, Content Committee, American Society for Transplantation and Cellular Therapy (ASTCT)
• Member, Plasma Cell Disorders Working Committee, CIBMTR

Dr. Banerjee serves as Principal Investigator for several clinical trials including 'Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation' and 'Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy.' His work has been presented at major hematology and oncology conferences including ASH, with recent contributions to research on potential functional cures for multiple myeloma and new endpoints that could accelerate drug approvals. Dr. Banerjee sees patients at Fred Hutch Cancer Center locations in South Lake Union and at UW Medical Center – Montlake and is fluent in English, Hindi, and Bengali.